1. Buyer

1.1 Buyer

Official name:	Leids Universitair Medisch Centrum (LUMC)
Legal type of the buyer:	Body governed by public law
Activity of the contracting authority:	Health

2. Procedure

2.1 Procedure

Title:	L-EU-24-13 Voluntary Transparency LC-MS / MS system
Description:	See added document L-EU-24-13 Vrijwillige transparantie... The contracting authority, Leiden University Medical Centre (LUMC) has the intention to acquire a ZenoTOF MS on behalf of the department Center for Proteomics and Metabolomics. LUMC has the intention to award the contract to AB Sciex Netherlands B.V (Sciex). Eerste Tochtweg 11, Nieuwerkerk a/d IJssel, 2913 LN Netherlands, NETHERLANDS . LUMC will apply the negotiation procedure without publication of a contract notice. LUMC has established that no other competitors than Sciex are, momentarily, able to meet some of the essential technical demands with respect to proven technology. The contracting authority may apply the negotiated procedure without prior notice because there is no competition for the following technical reasons and the relevant supply and service can only be provided by this specific supplier: 1. The acquired MS system must be capable of (patented) EIEIO fragmentation of lipids for full structural elucidation 1
Procedure identifier:	4fdb91c7-615b-453c-af2e-d4c1b6cbf08d
Internal identifier:	L-EU-24-13
Type of procedure:	Negotiated without prior call for competition

2.1.1 Purpose

Main nature of the contract:	Supplies
Main classification(cpv):	38433100Mass spectrometer

2.1.2 Place of performance

Country:	Netherlands

Anywhere in the given country

Additional information:	Leiden

2.1.4 General information

See added document L-EU-24-13 Vrijwillige transparantie... The contracting authority, Leiden University Medical Centre (LUMC) has the intention to acquire a ZenoTOF MS on behalf of the department Center for Proteomics and Metabolomics. LUMC has the intention to award the contract to AB Sciex Netherlands B.V (Sciex). Eerste Tochtweg

11, Nieuwerkerk a/d IJssel, 2913 LN Netherlands, NETHERLANDS . LUMC will apply the negotiation procedure without publication of a contract notice. LUMC has established that no other competitors than Sciex are, momentarily, able to meet some of the essential technical demands with respect to proven technology. The contracting authority may apply the negotiated procedure without prior notice because there is no competition for the following technical reasons and the relevant supply and service can only be provided by this specific supplier: 1. The acquired MS system must be capable of (patented) EIEIO fragmentation of lipids for full structural elucidation. 2. For metabolomics applications, the instrument must provide the following acquisition modes: TOF MS/MS, MRMHR, data independent acquisition (DIA)/SWATH scan mode using fixed and variable window acquisitions, and information dependent acquisition (IDA)/data dependent acquisition (DDA) scan modes. 3. For untargeted metabolomics, the instrument needs to enable the unambiguous identification of metabolites and peptides in complex matrices, using conventional (collision induced dissociation, CID) and reagent-free alternative (electron capture dissociation, ECD; “hot ECD”; and electron impact excitation of ions from organics, EIEIO) fragmentation approaches. The instrument must contain a time-of-flight (TOF) mass analyzer and enable sequential window acquisition of all theoretical mass spectra (SWATH) acquisition mode. The instrument must have an internal mass accuracy of <0.2 and <0.5 ppm for the fragment ions m/z 813 and m/z 120 of GluFibrinopeptide B, respectively. 4. For targeted metabolomics and proteomics, the scan speed for TOF-MS /MS must be >100 Hz to ensure the accurate quantitation of a large number of metabolites and peptides (> 300 metabolites) per run. The duty cycle (TOF-MS/MS) must be >90% for all ions, to enhance the sensitivity. The linear dynamic range must be 5 orders of magnitude in both ESI positive and negative modes. For both untargeted and targeted approaches, the sensitivity must be sufficiently high to allow for the detection and accurate quantitation of metabolites and peptides present at trace concentrations in biosamples. Therefore, the sensitivity must reach the following signal-to-noise (S/N) ratios: S/N 2500:1 using an ESI probe in full-scan TOF MS mode with a mass extraction window of 10 mDa for m/z 609.2806 for a 1 pg reserpine injection on column (ESI positive mode), and S/N 1000:1 using an ESI probe in full-scan TOF MS mode with a mass extraction window of 10 mDa for m/z 321.0050 for a 100 fg chloramphenicol injection on column (ESI negative mode). Suggested delivery ZenoTOF -LCMS system Conclusion By means of this call for voluntary ex ante transparency, LUMC informs parties of its intention and provides the opportunity to submit a reasoned objection against this intention. If parties have objections against the intended purchase from Sciex, please inform LUMC on the last appearance of [17-01-2024], before 17:00 h. by sending an email directed at: aanbestedingen@lumc.nl with reference to L-EU-24-13, Procurement. When during this term no objections have been raised, LUMC is free to acquire it’s desired Massaspectrometer from AB Sciex Netherlands B.V..

Additional information:

Legal basis:

Directive 2014/24/EU

5. Lot

5.1 Lot technical ID:LOT-0000

Title: L-EU-24-13 LC-MS / MS System

See added document L-EU-24-13 Vrijwillige transparantie... The contracting authority, Leiden University Medical Centre (LUMC) has the intention to acquire a ZenoTOF MS on behalf of the department Center for Proteomics and Metabolomics. LUMC has the intention to award the contract to AB Sciex Netherlands B.V (Sciex). Eerste Tochtweg 11, Nieuwerkerk a/d IJssel, 2913 LN Netherlands, NETHERLANDS . LUMC will apply the negotiation procedure without publication of a contract notice. LUMC has established that no other competitors than Sciex are, momentarily, able to meet some of the essential technical demands with respect to proven technology. The contracting authority may

Description:	apply the negotiated procedure without prior notice because there is no competition for the following technical reasons and the relevant supply and service can only be provided by this specific supplier: 1. The acquired MS system must be capable of (patented) EIEIO fragmentation of lipids for full structural elucidation. 2. For metabolomics applications, the instrument must provide the following acquisition modes: TOF MS/MS, MRMHR, data independent acquisition (DIA)/SWATH scan mode using fixed and variable window acquisitions, and information dependent acquisition (IDA)/data dependent acquisition (DDA) scan modes. 3. For untargeted metabolomics, the instrument needs to enable the unambiguous identification of metabolites and peptides in complex matrices, using conventional (collision induced dissociation, CID) and reagent-free alternative (electron capture dissociation, ECD; “hot ECD”; and electron impact excitation of ions from organics, EIEIO) fragmentation approaches. The instrument must contain a time-of-flight (TOF) mass analyzer and enable sequential window acquisition of all theoretical mass spectra (SWATH) acquisition mode. The instrument must have an internal mass accuracy of <0.2 and <0.5 ppm for the fragment ions m/z 813 and m/z 120 of GluFibrinopeptide B, respectively. 4. For targeted metabolomics and proteomics, the scan speed for TOF-MS /MS must be >100 Hz to ensure the accurate quantitation of a large number of metabolites and peptides (> 300 metabolites) per run. The duty cycle (TOF-MS/MS) must be >90% for all ions, to enhance the sensitivity. The linear dynamic range must be 5 orders of magnitude in both ESI positive and negative modes. For both untargeted and targeted approaches, the sensitivity must be sufficiently high to allow for the detection and accurate quantitation of metabolites and peptides present at trace concentrations in biosamples. Therefore, the sensitivity must reach the following signal-to-noise (S/N) ratios: S/N 2500:1 using an ESI probe in full-scan TOF MS mode with a mass extraction window of 10 mDa for m/z 609.2806 for a 1 pg reserpine injection on column (ESI positive mode), and S/N 1000:1 using an ESI probe in full-scan TOF MS mode with a mass extraction window of 10 mDa for m/z 321.0050 for a 100 fg chloramphenicol injection on column (ESI negative mode). Suggested delivery ZenoTOF -LCMS system Conclusion By means of this call for voluntary ex ante transparency, LUMC informs parties of its intention and provides the opportunity to submit a reasoned objection against this intention. If parties have objections against the intended purchase from Sciex, please inform LUMC on the last appearance of [17-01-2024], before 17:00 h. by sending an email directed at: aanbestedingen@lumc.nl with reference to L-EU-24-13, Procurement. When during this term no objections have been raised, LUMC is free to acquire it’s desired Massaspectrometer from AB Sciex Netherlands B.V.. 1
Internal identifier:	1

5.1.1 Purpose

Main nature of the contract:	Supplies
Main classification(cpv):	38433100Mass spectrometer

5.1.2 Place of performance

Country:	Netherlands

Anywhere in the given country

Additional information:	Leiden

5.1.3 Estimated duration

Duration:	120Month

5.1.5 Value

Estimated value excluding VAT:	350 000Euro

5.1.6 General information

Procurement Project not financed with EU Funds.

The procurement is covered by the Government Procurement Agreement (GPA):	yes

5.1.7 Strategic procurement

Aim of strategic procurement:	No strategic procurement

5.1.10 Award criteria

Criterion:

Type:	Cost
Name:	Best price/quality
Description:	See added document L-EU-24-13 Vrijwillige transparantie... The contracting authority, Leiden University Medical Centre (LUMC) has the intention to acquire a ZenoTOF MS on behalf of the department Center for Proteomics and Metabolomics. LUMC has the intention to award the contract to AB Sciex Netherlands B.V (Sciex). Eerste Tochtweg 11, Nieuwerkerk a/d IJssel, 2913 LN Netherlands, NETHERLANDS . LUMC will apply the negotiation procedure without publication of a contract notice. LUMC has established that no other competitors than Sciex are, momentarily, able to meet some of the essential technical demands with respect to proven technology. The contracting authority may apply the negotiated procedure without prior notice because there is no competition for the following technical reasons and the relevant supply and service can only be provided by this specific supplier: 1. The acquired MS system must be capable of (patented) EIEIO fragmentation of lipids for full structural elucidation. 2. For metabolomics applications, the instrument must provide the following acquisition modes: TOF MS/MS, MRMHR, data independent acquisition (DIA)/SWATH scan mode using fixed and variable window acquisitions, and information dependent acquisition (IDA)/data dependent acquisition (DDA) scan modes. 3. For untargeted metabolomics, the instrument needs to enable the unambiguous identification of metabolites and peptides in complex matrices, using conventional (collision induced dissociation, CID) and reagent-free alternative (electron capture dissociation, ECD; “hot ECD”; and electron impact excitation of ions from organics, EIEIO) fragmentation approaches. The instrument must contain a time-of-flight (TOF) mass analyzer and enable sequential window acquisition of all theoretical mass spectra (SWATH) acquisition mode. The instrument must have an internal mass accuracy of <0.2 and <0.5 ppm for the fragment ions m/z 813 and m/z 120 of GluFibrinopeptide B, respectively. 4. For targeted metabolomics and proteomics, the scan speed for TOF-MS /MS must be >100 Hz to ensure the accurate quantitation of a large number of metabolites and peptides (> 300 metabolites) per run. The duty cycle (TOF-MS/MS) must be >90% for all ions, to enhance the sensitivity. The linear dynamic range must be 5 orders of magnitude in both ESI positive and negative modes. For both untargeted and targeted approaches, the sensitivity must be sufficiently high to allow for the detection

	and accurate quantitation of metabolites and peptides present at trace concentrations in biosamples. Therefore, the sensitivity must reach the following signal-to-noise (S/N) ratios: S/N 2500:1 using an ESI probe in full-scan TOF MS mode with a mass extraction window of 10 mDa for m/z 609.2806 for a 1 pg reserpine injection on column (ESI positive mode), and S/N 1000:1 using an ESI probe in full-scan TOF MS mode with a mass extraction window of 10 mDa for m/z 321.0050 for a 100 fg chloramphenicol injection on column (ESI negative mode). Suggested delivery ZenoTOF -LCMS system Conclusion By means of this call for voluntary ex ante transparency, LUMC informs parties of its intention and provides the opportunity to submit a reasoned objection against this intention. If parties have objections against the intended purchase from Sciex, please inform LUMC on the last appearance of [17-01-2024], before 17:00 h. by sending an email directed at: aanbestedingen@lumc.nl with reference to L-EU-24-13, Procurement. When during this term no objections have been raised, LUMC is free to acquire it's desired Massaspectrometer from AB Sciex Netherlands B.V..
Weight (points, exact):	100

5.1.15 Techniques

Framework agreement:

No framework agreement

Information about the dynamic purchasing system:

No dynamic purchase system

5.1.16 Further information, mediation and review

Review organisation:	Leids Universitair Medisch Centrum (LUMC)
Organisation providing additional information about the procurement procedure:	Leids Universitair Medisch Centrum (LUMC)
Organisation providing more information on the review procedures:	Leids Universitair Medisch Centrum (LUMC)
Organisation signing the contract:	Leids Universitair Medisch Centrum (LUMC)

6. Results

Value of all contracts awarded in this notice:	350 000Euro
Direct award:	
Justification for direct award:	The contract can be provided only by a particular economic operator because of an absence of competition for technical reasons

Other justification:	See added document L-EU-24-13 Vrijwillige transparantie... The contracting authority, Leiden University Medical Centre (LUMC) has the intention to acquire a ZenoTOF MS on behalf of the department Center for Proteomics and Metabolomics. LUMC has the intention to award the contract to AB Sciex Netherlands B.V (Sciex). Eerste Tochtweg 11, Nieuwerkerk a/d IJssel, 2913 LN Netherlands, NETHERLANDS . LUMC will apply the negotiation procedure without publication of a contract notice. LUMC has established that no other competitors than Sciex are, momentarily, able to meet some of the essential technical demands with respect to proven technology. The contracting authority may apply the negotiated procedure without prior notice because there is no competition for the following technical reasons and the relevant supply and service can only be provided by this specific supplier: 1. The acquired MS system must be capable of (patented) EIEIO fragmentation of lipids for full structural elucidation. 2. For metabolomics applications, the instrument must provide the following acquisition modes: TOF MS/MS, MRMHR, data independent acquisition (DIA)/SWATH scan mode using fixed and variable window acquisitions, and information dependent acquisition (IDA)/data dependent acquisition (DDA) scan modes. 3. For untargeted metabolomics, the instrument needs to enable the unambiguous identification of metabolites and peptides in complex matrices, using conventional (collision induced dissociation, CID) and reagent-free alternative (electron capture dissociation, ECD; “hot ECD”; and electron impact excitation of ions from organics, EIEIO) fragmentation approaches. The instrument must contain a time-of-flight (TOF) mass analyzer and enable sequential window acquisition of all theoretical mass spectra (SWATH) acquisition mode. The instrument must have an internal mass accuracy of <0.2 and <0.5 ppm for the fragment ions m/z 813 and m/z 120 of GluFibrinopeptide B, respectively. 4. For targeted metabolomics and proteomics, the scan speed for TOF-MS /MS must be >100 Hz to ensure the accurate quantitation of a large number of metabolites and peptides (> 300 metabolites) per run. The duty cycle (TOF-MS/MS) must be >90% for all ions, to enhance the sensitivity. The linear dynamic range must be 5 orders of magnitude in both ESI positive and negative modes. For both untargeted and targeted approaches, the sensitivity must be sufficiently high to allow for the detection and accurate quantitation of metabolites and peptides present at trace concentrations in biosamples. Therefore, the sensitivity must reach the following signal-to-noise (S/N) ratios: S/N 2500:1 using an ESI probe in full-scan TOF MS mode with a mass extraction window of 10 mDa for m/z 609.2806 for a 1 pg reserpine injection on column (ESI positive mode), and S/N 1000:1 using an ESI probe in full-scan TOF MS mode with a mass extraction window of 10 mDa for m/z 321.0050 for a 100 fg chloramphenicol injection on column (ESI negative mode). Suggested delivery ZenoTOF -LCMS system Conclusion By means of this call for voluntary ex ante transparency, LUMC informs parties of its intention and provides the opportunity to submit a reasoned objection against this intention. If parties have objections against the intended purchase from Sciex, please inform LUMC on the last appearance of [17-01-2024], before 17:00 h. by sending an email directed at: aanbestedingen@lumc.nl with reference to L-EU-24-13, Procurement. When during this term no objections have been raised, LUMC is free to acquire it’s desired Massaspectrometer from AB Sciex Netherlands B.V..

6.1 Result lot ldentifier:LOT-0000

At least one winner was chosen.

6.1.2 Information about winners

Winner:	
Official name:	AB Sciex Netherlands B.V.
Tender:	
Tender identifier:	1

Identifier of lot or group of lots:	LOT-0000
Value of the tender:	350 000Euro
The tender was ranked:	no
The tender is a variant:	no
Subcontracting:	No

Contract information:

Identifier of the contract:	CON-0001
Title:	P1 L-EU-24-13 LC-MS / MS System
Date on which the winner was chosen:	23/12/2024
Date of the conclusion of the contract:	23/12/2024
The contract is awarded within a framework agreement:	no
Organisation signing the contract:	Leids Universitair Medisch Centrum (LUMC)

6.1.4 Statistical information

Received tenders or requests to participate:

Type of received submissions:	Tenders from micro, small or medium tenderers
Number of tenders or requests to participate received:	1
Type of received submissions:	Tenders
Number of tenders or requests to participate received:	1

8. Organisations

8.1 ORG-0001

Official name:	Leids Universitair Medisch Centrum (LUMC)
Registration number:	141696672
Postal address:	Albinusdreef 2
Town:	LEIDEN
Postcode:	2333ZA
Country subdivision (NUTS):	Agglomeratie Leiden en Bollenstreek(NL337)
Country:	Netherlands
Contact point:	Jimmy Been
Email:	aanbestedingen@lumc.nl
Telephone:	+31 715299611
Internet address:	http://www.lumc.nl

Other contact points:

Official name:	Rechtbank Den Haag
Town:	Den Haag
Postcode:	2500EH
Country subdivision (NUTS):	Agglomeratie ’s-Gravenhage(NL332)
Country:	Netherlands
Email:	aanbestedingen@lumc.nl
Internet address:	https://www.rechtspraak.nl/Organisatie-en-contact/Organisatie/Rechtbanken/Rechtbank-Den-Haag

Roles of this organisation:

Buyer

Organisation providing additional information about the procurement procedure

Review organisation

Organisation providing more information on the review procedures

Organisation signing the contract

8.1 ORG-0002

Official name:	AB Sciex Netherlands B.V.
Size of the economic operator:	Micro, small, or medium
Registration number:	34271324
Postal address:	1e Tochtweg 11
Town:	Nieuwerkerk aan den IJssel
Postcode:	2913LN
Country subdivision (NUTS):	Agglomeratie Leiden en Bollenstreek(NL337)

Country:	Netherlands

Roles of this organisation:

Tenderer

Winner of these lots:	LOT-0000

11. Notice information

11.1 Notice information

Notice identifier /version:	97641155-a4f7-44f4-b645-f444599df289-01
Form type:	Result
Notice type:	Contract or concession award notice – standard regime
Notice dispatch date:	24/12/202418:01 +01:00
Languages in which this notice is officially available:	English

11.2 Publication information